Assessing the clinical impact of tumor volume on response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
Findings showed darolutamide reduced the risk of radiographic progression or death by 46% compared with placebo. The Food and Drug Administration (FDA) has approved Nubeqa ® (darolutamide), an ...
Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis The standard of care for ...
In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...
The journey through prostate cancer treatment marks a significant chapter in many men’s lives, with surgery often serving as a pivotal turning point toward recovery. While the removal of cancerous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results